Elif Çiğdem KASPAR, Caner YÜRÜYEN, Sabire Ferda KALEAĞASIOĞLU, Yeşim GÜROL, Gülden YILMAZ

Isolation rates and antibiotic susceptibilities of different Enterobacteriaceae species as urinary tract infection agents in Turkey: a systematic review

Background/aim: In Turkey, few systematic reviews have analyzed the results of studies on the isolation rates of urinary tract infection agents and their antibiotic susceptibilities. This review was done to fill this gap and enable the correct application of guideline-based medical therapy by determining the isolation rates and antibiotic susceptibilities of different Enterobacteriaceae species in Turkey. Materials and methods: Relevant studies found from various databases with the help of previously specified search strategies were examined and eliminated according to eligibility criteria. The remaining 22 studies were included in this systematic review. Results: Escherichia coli was the most frequently isolated species among all agents in both in- and outpatient settings. Only the antibiotic susceptibility data of E. coli could be analyzed because among the 22 studies only E. coli had adequate antibiotic susceptibility data to be analyzed. The calculated resistance rates of the most frequently preferred antibiotics (trimethoprim/sulfamethoxazole, ciprofloxacin, and ceftriaxone) were 46%, 32%, and 19% for outpatients and 54%, 48%, and 28% for inpatients, respectively. Conclusion: The resistance profiles of commonly used antimicrobial agents are much higher than the thresholds set by international guidelines. Hence, treatment algorithms for urinary tract infections should be designed according to Turkey s antimicrobial resistance patterns.

PDF

___

1. Doğru A, Üçışık AC, Sargın F, Aydın Ö, Ergen P, Tükenmez Tigen E. Extended spectrum b-lactamase and antibiotic suspectibility of Escherichia coli grown in urinary isolates. Göztepe Tıp Dergisi 2014; 29: 219-224 (in Turkish with an abstract in English).
2. Doğru A, Karatoka B, Ergen P, Aydın ÖŞ, Tükenmez Tigen E. The resistance rates of urinary tract infections: our data from year 2010. Turk J Urol 2013; 39: 237-243.
3. Aypak C, Altunsoy A, Düzgün N. Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study. Ann Clin Microbiol Antimicrob 2009; 8: 27.
4. Zengin K, Tanık S, Albayrak S, Kaba M, Pirinççi N. The urinary system infectious agents and their antibiotics susceptibilities in Van district. Bozok Tıp Dergisi 2014; 4: 1-5 (in Turkish with an abstract in English).
5. Naz H, Çevik FÇ, Aykın N. Nosocomial urinary tract infections and resistance profile to antibiotics. Dicle Tıp Dergisi 2009; 36: 85-90 (in Turkish with an abstract in English).
6. Arslan B, Kozacıoğlu Z, Yüksel Ergin Ö, Bozkurt İH, Değirmenci T, Yonguç T, Günlüsoy B. Pathogen bacteria of the urinary tract isolated from urine cultures and their susceptibility. Erciyes Medical Journal 2014; 36: 29-34.
7. Ağca H, Toklu GD. Bacteria isolated from urine samples and their antimicrobial susceptibilities. Journal of Clinical and Analytical Medicine 2013; 4: 30-33 (in Turkish with an abstract in English).
8. Ağca H. Bacteria isolated from urine samples and their antimicrobial susceptibilities. Kocatepe Tıp Dergisi 2011; 12: 95-100 (in Turkish with an abstract in English).
9. Geçit İ, Yücel M, Kebeci F, Özaydın Ç, Öksüz Ş, Yavuz T. The bacteria isolated from the urine cultures of patients admitted to Düzce Atatürk State Hospital urology outpatient clinic and their antibiotic resistances. Konuralp Tıp Dergisi 2013; 5:34-37 (in Turkish with an abstract in English).
10. Kandemir Ö, Akdağ A, Kurt AÖ. Antibiotic susceptibility of bacterial strains isolated from patients with community acquired urinary tract infections in Mersin. TAF Preventive Medicine Bulletin 2012; 11: 589-598 (in Turkish with an abstract in English).
11. Rifaioğlu MM, Yıldırım A, Başok EK, Keskin SK, Özgüneş N, Tokuç R. Changing pattern of antibiotic resistance of bacterias isolated from urine cultures in the last four years. Türk Üroloji Dergisi 2009; 35: 201-209 (in Turkish with an abstract in English).
12. Yıldırım M, Şahin İ, Gülcan A, Özdemir D, Küçükbayrak A, Uzun H, Kaya D. Antimicrobial susceptibility and uropathogens isolated from children and adults with community-acquired urinary tract infections. Turk Klin Tıp Bilim 2010; 30: 533-538.
13. Köksaldı Motor V, Tutanç M, Arıca V, Arıca S, Ay B. Susceptibility of uropathogen Escherichia coli strains to commonly used antibacterial agents in urinary tract infections. ANKEM Dergisi 2010; 24: 198-201 (in Turkish with an abstract in English).
14. Isikgoz Tasbakan M, Durusoy R, Pullukcu H, Sipahi OR, Ulusoy S; 2011 Turkish Nosocomial Urinary Tract Infection Study Group. Hospital-acquired urinary tract infection point prevalence in Turkey: differences in risk factors among patient groups. Ann Clin Microbiol Antimicrob 2013, 12: 31.
15. Karakeçili F, Karadağ S, Erbay F, Yılmaz E, Akalın H, Özakin C, Özmen A, Mıstık R, Helvacı S. Pyelonephritis: a retrospective analysis of 190 cases. Klimik Dergisi 2010; 23: 10-14 (in Turkish with an abstract in English).
16. Yilmaz N, Agus N, Yurtsever SG, Pullukcu H, Gulay Z, Coskuner A, Kose S, Aydemir S, Gulenc N, Ozgenc O. Prevalence and antimicrobial susceptibility of Escherichia coli in outpatient urinary isolates in Izmir, Turkey. Med Sci Monitor 2009; 15: PI61-165.
17. Kurtaran B, Candevir A, Tasova Y, Kibar F, Inal AS, Komur S, Aksu HSZ. Antibiotic resistance in community-acquired urinary tract infections: prevalence and risk factors. Med Sci Monitor 2010; 16: CR246-251.
18. Arman D, Ağalar C, Dizbay M, Tunçcan ÖG, Keten DT, Aygün G, Tünger Ö, Demirtürk N, İnan D, Özakın C et al. Community acquired lower urinary tract infections in primary care: causative agents and antimicrobial susceptibility. Mediterranean Journal of Infection, Microbes & Antimicrobials 2012; 1: 1-8 (in Turkish with an abstract in English).
19. Sağlam HS, Öğütlü A, Demiray V, Karabay O. The role of Escherichia colis in community acquired urinary infections and developing antibiotic resistance. Nobel Med 2012; 8: 67-71 (in Turkish with an abstract in English).
20. Guneysel O, Onur O, Erdede M, Denizbasi A. Trimethoprim/ sulfamethoxazole resistance in urinary tract infections. J Emerg Med 2009; 36: 338-341.
21. Geçit İ, Benli E, Karakoç S, Şahin MA, Hoto D. Evaluation of antimicrobial resistance emerging against pathogens leading to infection of urinary in our region. Tıp Araştırmaları Dergisi 2011; 9: 115-119 (in Turkish with an abstract in English).
22. Ceylan C, Doğan S, Şen S, Odabaş Ö. The relationship between catheterisation and nosocomial urinary tract infections in our clinic and bacterial prevalance: a retrospective study. Van Tıp Dergisi 2012; 19: 21-26 (in Turkish with an abstract in English).
23. Yüksel MB. The evaluation of the common pathogenic microorganisms in uncomplicated urinary tract infections and the antibiotic susceptibilities in daily practice. New Journal of Urology 2011; 6: 17-21.
24. Işıkgöz Taşbakan M, Şenol Ş, Şimşir A, Pullukçu H, Kahraman H, Sipahi OR, Yamazhan T, Arda B, Kısmalı E, Tünger A et al. Evaluation of 133 patients with acute pyelonephritis. ANKEM Dergisi 2011; 25: 157-163 (in Turkish with an abstract in English).
25. Uluğ M, Gül İ. Investigation of the results of urine cultures and approaches to empirical antibiotic treatment of communityacquired urinary tract infections in elderly patients. Klimik Dergisi 2013; 25: 71-76 (in Turkish with an abstract in English).
26. Aykan ŞB, Çiftçi İH. Antibiotic resistance patterns of Escherichia coli strains isolated from urine cultures in Turkey: a meta-analysis. Mikrobiyol Bul 2013; 47: 603-618 (in Turkish with an abstract in English).
27. Arısoy ES. T.C. Sağlık Bakanlığı Birinci Basamağa Yönelik Tanı ve Tedavi Rehberleri. 1st ed. Ankara, Turkey: T.C. Sağlık Bakanlığı; 2003 (in Turkish).
28. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: 103-120.
29. Yarış E. T.C. Sağlık Bakanlığı Birinci Basamağa Yönelik Tanı ve Tedavi Rehberleri. 2nd ed. Ankara, Turkey: T.C. Sağlık Bakanlığı; 2012 (in Turkish).
30. Grabe M, Bartoletti R, Johansen TEB, Cai T, Çek M, Köves B, Naber KG, Pickard RS, Tenke P, Wagenlehner F et al. Guidelines on Urological Infections. Arnhem, the Netherlands: European Association of Urology; 2015.
31. Peterson LR. Antibiotic policy and prescribing strategies for therapy of extended-spectrum B-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 2008; 14: 181-184.
32. De La Blanchardière A, Dargère S, Guérin F, Daurel C, SaintLorant G, Verdon R, Cattoir V. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae. Med Mal Infect 2015; 45: 169-172.
33. Ng TM, Khong WX, Harris PNA, De PP, Chow A, Tambyah PA, Lye DC. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. PLoS One 2016; 11: e0153696.
34. Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J et al. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone nonsusceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials 2015; 16: 24.